254 related articles for article (PubMed ID: 19690820)
1. National assessment of Medicare prescription plan coverage gaps among patients with atrial fibrillation in the US.
Kim MH; Lin J; Kreilick C
Adv Ther; 2009 Aug; 26(8):784-94. PubMed ID: 19690820
[TBL] [Abstract][Full Text] [Related]
2. Cost of atrial fibrillation in United States managed care organizations.
Kim MH; Lin J; Hussein M; Kreilick C; Battleman D
Adv Ther; 2009 Sep; 26(9):847-57. PubMed ID: 19768638
[TBL] [Abstract][Full Text] [Related]
3. The Medicare Part D doughnut hole: effect on pharmacy utilization.
Sun SX; Lee KY
Manag Care Interface; 2007 Sep; 20(9):51-5, 59. PubMed ID: 18161394
[TBL] [Abstract][Full Text] [Related]
4. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
5. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
[TBL] [Abstract][Full Text] [Related]
6. Assessment of drug consumption patterns for Medicare Part D patients.
Pedan A; Lu J; Varasteh LT
Am J Manag Care; 2009 May; 15(5):323-7. PubMed ID: 19435400
[TBL] [Abstract][Full Text] [Related]
7. Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors.
Amin AN; Jhaveri M; Lin J
Adv Ther; 2011 Oct; 28(10):907-26. PubMed ID: 21971681
[TBL] [Abstract][Full Text] [Related]
8. Analysis of national annual variation in total patient out-of-pocket Medicare Part D stand-alone prescription drug plan costs from 2007 to 2008.
Walberg MP; Patel RA; Amaral MM
J Med Econ; 2008; 11(4):625-37. PubMed ID: 19450072
[TBL] [Abstract][Full Text] [Related]
9. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States.
Kim MH; Johnston SS; Chu BC; Dalal MR; Schulman KL
Circ Cardiovasc Qual Outcomes; 2011 May; 4(3):313-20. PubMed ID: 21540439
[TBL] [Abstract][Full Text] [Related]
10. Who will be denied Medicare prescription drug subsidies because of the asset test?
Rice T; Desmond K
Am J Manag Care; 2006 Jan; 12(1):46-54. PubMed ID: 16402888
[TBL] [Abstract][Full Text] [Related]
11. Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy.
Kim MH; Lin J; Hussein M; Battleman D
Curr Med Res Opin; 2009 Dec; 25(12):3037-47. PubMed ID: 19852699
[TBL] [Abstract][Full Text] [Related]
12. Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed.
Boccuzzi SJ; Martin J; Stephenson J; Kreilick C; Fernandes J; Beaulieu J; Hauch O; Kim J
Curr Med Res Opin; 2009 Dec; 25(12):2853-64. PubMed ID: 19916729
[TBL] [Abstract][Full Text] [Related]
13. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
14. Impact of Medicare Part D for Medicare-age adults with arthritis: prescription use, prescription expenditures, and medical spending from 2005 to 2008.
Cheng LI; Rascati KL
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1423-9. PubMed ID: 22508663
[TBL] [Abstract][Full Text] [Related]
15. Medicare Part D--the sea of choices meets the donut hole.
Flaer PJ; Dondériz A; Younis MZ
J Health Care Finance; 2007; 34(1):1-7. PubMed ID: 18972980
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population.
Davis KL; Candrilli SD; Edin HM
Epilepsia; 2008 Mar; 49(3):446-54. PubMed ID: 18031549
[TBL] [Abstract][Full Text] [Related]
17. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
18. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population.
Menzin J; Boulanger L; Marton J; Guadagno L; Dastani H; Dirani R; Phillips A; Shah H
Respir Med; 2008 Sep; 102(9):1248-56. PubMed ID: 18620852
[TBL] [Abstract][Full Text] [Related]
19. Outpatient prescription drug utilization and expenditure patterns of noninstitutionalized aged Medicare beneficiaries.
LaVange LM; Silverman HA
Natl Med Care Util Expend Surv B; 1987 Apr; (12):1-43. PubMed ID: 10313516
[TBL] [Abstract][Full Text] [Related]
20. The use of disease-modifying agents among multiple sclerosis patients enrolled in medicare from 1995 to 2002 and the impact of medicare part D: analysis of claims data from the medicare current beneficiary survey.
Lundy J; Craig BM
Clin Ther; 2006 Jan; 28(1):140-5. PubMed ID: 16490588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
